Chloroquine and hydroxychloroquine in the context of COVID-19

Ashutosh M Shukla; Lennox K Archibald; Aparna Wagle Shukla; Hiren J Mehta; Kartikeya Cherabuddi

doi:10.7573/dic.2020-4-5

Chloroquine and hydroxychloroquine in the context of COVID-19

Drugs Context. 2020 Apr 28:9:2020-4-5. doi: 10.7573/dic.2020-4-5. eCollection 2020.

Authors

Ashutosh M Shukla^{1

2}, Lennox K Archibald^{1

2}, Aparna Wagle Shukla³, Hiren J Mehta², Kartikeya Cherabuddi²

Affiliations

¹ North Florida South Georgia VHS, Gainesville, FL, USA.
² Department of Medicine, University of Florida, Gainesville, FL, USA.
³ Department of Neurology, University of Florida, Gainesville, FL, USA.

Abstract

Chloroquine and closely related structural analogs, employed initially for the treatment of malaria, are now gaining worldwide attention due to the rapidly spreading pandemic caused by severe acute respiratory syndrome-coronavirus-2, named coronavirus disease (COVID) of 2019 (COVID-19). Although much of this attention has a mechanistic basis, the hard efficacy data for chloroquine/hydroxychloroquine in the management of the clinical syndrome of COVID-19 have been limited thus far. This review aims to present the available in vitro and clinical data for the role of chloroquine/hydroxychloroquine in COVID-19 and attempts to put them into perspective, especially in relation to the different risks/benefits particular to each patient who may require treatment.

Keywords: COVID-19; SARS-CoV-2; anti-inflammatory; antimalarial; antiviral; chloroquine; hydroxychloroquine; immunomodulatory; pandemic.

Publication types

Review

Abstract

Publication types

Grants and funding